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1. Introduction
ING1 is a type II tumor suppressor that affects cell growth, 
apoptosis, and senescence by altering chromatin structure and 
regulates transcription (Garkavtsev et al., 1996; Russell et al., 
2006; Coles and Jones, 2009; Li et al., 2011). The most widely 
expressed ING1 isoform is p33(ING1b) and downregulation 
of nuclear p33(ING1b) expression was associated with more 
poorly differentiated tumors in invasive breast carcinoma 
(Nouman et al., 2003a). Furthermore, it has been shown that 
the transfer of p33(ING1b) protein from the nucleus to the 
cytoplasm may result in the loss of normal cellular function 
of the protein. This might play a role in tumorigenesis and 
lymph node metastasis of oral squamous cell carcinomas as 
well as esophageal squamous cell carcinoma (Zhang et al., 
2008; Zhu et al., 2012). Several studies showed that nuclear 
import of p33(ING1b) occurs concomitantly with physical 
and/or functional interactions with a subset of nuclear 
proteins, including p53, p300/CBP, and HDAC1 in different 
models. However, little is known about the way and the 
importance of nuclear localization (Feng et al., 2002; Kataoka 
et al., 2003; Nouman et al., 2003b). p33(ING1b) may also 
have a role in estrogen-dependent signaling in mammalian 
cells. It was shown that p33(ING1b) interacts directly with 
the activation function 2 (AF2) domain of estrogen receptor 
α (ERα) and modulates the transcriptional activity of an E2-
responsive reporter construct in a dose-dependent manner 
as well (Toyama et al., 2003). ING1 might help and/or 
contribute to the regulation of ERα-dependent target gene 
expression through the facilitation of a localized relaxation 
in chromatin compaction surrounding ERα-responsive 
genes and it might have a role in the development of breast 
cancers (Margueron et al., 2004; Doyon et al., 2006).
Therefore, it is critical to explain how the nuclear 
export of p33(ING1b) is regulated in ER signaling.
In the present study, we firstly demonstrated an 
abundant nuclear localization of p33(ING1b) in ERα 
expressing human invasive breast carcinoma tissues. 
Then we showed 17β-estrodiol (E2) induction enhanced 
localization of p33(ING1b) into the nucleus in ER 
α-positive breast cancer cell lines in vitro. 
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2. Materials and methods 
2.1. Cell lines and culture 
Human breast adenocarcinoma cell lines, MDA-MB-231 
(ERα negative) and MDA-66 (ERα-positive), were used in 
this study. MDA-66 was produced by stable transfection of 
MDA-MB-231 with human ER expression vector (pCMV-
ERα) (Alotaibi et al., 2006).
Both cell lines were maintained in high glucose 
Dulbecco’s modified Eagle’s medium [Gibco, (CA, USA) 
supplemented with 10% fetal bovine serum (FBS), 1% 
penicillin/streptomycin (P/S), and 1% L-glutamine 
(Biochrom, Berlin, Germany)] at 37 °C in a 5% CO2 
incubator. MDA-66 was maintained in the above medium 
with the addition of 0.4 mg/mL hygromycin (Roche, 
Penzberg Germany). In general, hormone induction 
experiments were performed in sf-DMEM (a phenol 
red-free DMEM supplemented with 10% dextran-coated-
charcoal stripped FBS, 1% P/S, and 1% L-glutamine) 
unless otherwise mentioned. Two days before the addition 
of hormone, cells were fed with sf-DMEM in order to 
deplete the culture media from endogenous steroids and 
retinoids. E2 was applied to a final concentration of 10 nM 
for 3 h. 
2.2. Patients and tissues
The patients studied comprised a series of 93 women with 
invasive breast carcinoma of mean age 54, ranging from 32 
to 65 years. These patients were diagnosed at the Hospital 
of the Medical School of Dokuz Eylül University, İzmir, 
Turkey, between 1991 and 2006. Routinely processed, 
formalin fixed, paraffin wax embedded blocks were 
retrieved from the archives. The Ethics Committee of 
Dokuz Eylül University Medical School approved the 
study.
2.3. Immunostaining
Five-micrometer-thick sections from the paraffin-
embedded formalin-fixed blocks were used for 
immunostaining following deparaffinization with xylene/
alcohol and were subjected to antigen retrieval using a 
microwave in Tris-EDTA buffer (pH 8.0) for 20 min. 
Mouse monoclonal anti-p33 (ING1b) antibody (Clone 
15B9 produced by Dr R Çetin Atalay) was used with 1:5 
dilution as followed in the Dako EnVision + Dual (DAKO, 
Denmark) method according to the manufacturer’s 
instructions. This antibody has been tested for its specificity 
in different cell lines (Sayan et al., 2009). The signals were 
detected using diaminobenzidine (DAB) staining after the 
specimens were counterstained with hematoxylin. For the 
staining of adherent cells grown on coverslips, the same 
protocol starting with primary antibody incubation was 
followed after methanol fixation and blocking with 5% 
fetal calf serum (FCS) in phosphate-buffered saline (PBS). 
For immunofluorescence staining of cells grown on 
coverslips, cells were fixed by 4% paraformaldehyde (PFA) 
for 15 min and permeabilized using 0.25% Triton X-100 
for 10 min. Nonspecific protein binding was blocked 
by incubation with 10% FCS for 30 min in PBS at room 
temperature (RT). Cells were then incubated with both 
mouse monoclonal anti-p33(ING1b) antibody (1:10) and 
rabbit polyclonal anti-ERα antibody (Millipore 06-935) 
(1:50) together in PBS containing 0.25% Triton X-100 
(PBS-T) and 3% FCS for 2 h at RT. After washing three times 
with PBS-T for 30 min, cells were further incubated with 
goat anti-mouse IgG antibody, (H + L) FITC conjugated 
(Millipore AP124F) (1:2000) and goat anti-rabbit IgG 
antibody, rhodamine conjugated (Millipore AP132R) 
(1:2000) for 1 h at RT. Counterstaining was performed 
by DAPI staining (1:500) for 5 min. After the slides were 
mounted using fluorescence-mounting medium (Dako), 
they were examined using an Olympus BX61 fluorescence 
microscope. 
2.4. Scoring 
The intensities of nuclear and cytoplasmic staining for 
p33ING1b on the cells were assessed on a four-point scale 
as follows: (0) for 0%–25%; (+) for 26%-50%; (++) for 
51%–75%, and (+++) for 76%–100%. This scoring system 
was used for all proteins studied. 
2.5. Western blotting 
Cells were washed and scraped with ice-cold PBS on 
ice and centrifuged at 5000 rpm for 5 min. A ProteoJET 
Cytoplasmic and Nuclear Protein Extraction Kit 
(Fermentas K0311) was used to extract protein according 
to the manufacturer’s instructions. 
Protein concentration was determined by BCA assay 
under the manufacturer’s instructions (Pierce 23225). The 
proteins were then resolved by sodium dodecyl sulfate 
polyacrylamide gel electrophoresis (SDS-PAGE) and 
transferred to PVDF membrane (Roche 03010040001, 
Mannheim Germany). The membrane was blocked with 
nonfat milk and immunoblotted with anti- p33(ING1b) 
antibody (1:100) and anti-ERα antibody (Millipore 06-
935) (1:500), separately. The unbound antibody was 
washed with TBS-T and the membrane was incubated 
with horseradish peroxidase-conjugated secondary 
antibody (Pierce 32430, 32460) and Super Signal West 
Dura Extended Duration Substrate (Pierce 34076) was 
used for detection. Mouse monoclonal anti-PCNA (PC10) 
antibody (Abcam ab29) (1:500) and rabbit polyclonal anti-
Calnexin (H-70) antibody (Santa Cruz-11397) (1:1000) 
were used as loading controls for nuclear and cytoplasmic 
fractions, respectively.
2.6. Statistical analysis 
To assess the relations between nuclear and/or cytoplasmic 
p33ING1b and ERα expression in tumor tissues the chi-
square statistical test was applied by using SPSS. 
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3. Results 
3.1. Subcellular expression of p33(ING1b) in invasive 
ductal breast carcinoma tissues 
Ninety-three invasive breast carcinoma tissues were 
analyzed for the presence of ERα and for the localization 
of p33(ING1b). The tumor tissue series used in this study 
comprised 53 cases of invasive ductal carcinomas, 19 
invasive lobular carcinomas, 9 medullary carcinomas, 
and 4 papillary, 5 metastatic, and 3 mucinous breast 
carcinomas. 
Among the 93 cases studied, p33(ING1b) staining in 
either the nuclear or cytoplasmic part of the tumor was 
seen in 63 samples (68%), while 29 out of the 93 samples 
(31%) showed staining in both compartments. Only one 
case (1%) did not show p33(INGb) staining in either the 
cytoplasm or in the nucleus. Figure 1 shows an example for 
strong p33(INGb) expression in the nucleus or cytoplasm 
of a tumor cell.
3.2. Increased nuclear expression of p33(ING1b) in 
estrogen receptor alpha positive breast carcinoma 
sections
In order to determine whether there is a correlation 
between p33(ING1b) localization and ERα expression, 
subcellular localization of p33(ING1b) expression was 
compared between ERα-positive and ERα-negative breast 
tumor sections (Table 1). Based on immunohistochemical 
staining data, cytoplasmic expression of p33(ING1b) was 
statistically more evident in ERα-negative sections, while 
a striking shift to nuclear expression was observed in 
ERα expressing tumors. These results indicated that ERα 
expression in invasive breast carcinoma might influence 
a shift in the localization of p33(ING1b) towards the 
nucleus. Furthermore, when intensities of p33(ING1b) 
staining were analyzed in these tissues, no significance 
difference was observed (data not shown).
3.3. Estradiol activated ERα promotes nuclear 
localization of p33 (ING1b) in breast carcinoma cell line 
To further study the effect of ERα on the subcellular 
localization of p33(ING1b) in breast carcinoma cells, 
we carried out immunostaining experiments using 
p33(ING1b) antibody in MDA-MB-231, an ERα negative 
breast adenocarcinoma cell line, and its stable clone 
ectopically expressing ERα and MDA-66 cells. Under 
steroid-free conditions p33(ING1b) expression was more 
abundant in the cytoplasm of MDA-MB-231 as well as 
MDA-66 (Figure 2). However, treatment with 17β-estradiol 
(A)  (B)  
 ×  100  ×  100  
Figure 1. Positive p33(ING1b) immunohistochemical staining. (A) Invasive lobular breast carcinoma tissue strongly expressing 
p33(ING1b) only in the nuclei of tumor cells. (B) Invasive ductal breast carcinoma tissue strongly expressing p33(ING1b) in the 
cytoplasm of tumor cells. 
Table 1. Relationship between compartmental p33(ING1b) expression and ERα expressions in 
invasive breast carcinoma.
p33(ING1b) expression ERα (–) (number of cases) ERα (+) (number of cases)
Only in cytoplasm 22 10
In cytoplasm and nucleus 13 16
Only in nucleus 4 27
ND 1 -
*P < 0.001, ND = Not determined
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(E2) caused a significant increase in the percentage of cells 
with nuclear staining only in the ERα-expressing cells 
(MDA-66) compared to the ERα-negative ones (MDA-
MB-231) (Figure 2). We further analyzed approximately 
300 cells in each condition to determine the percentage 
of cells expressing p33(ING1b) in the cytoplasm only, 
cytoplasm/nuclear, and nuclear only among the cells under 
estradiol induction as well as control in both cell lines. 
The results revealed that 17β-estradiol induction (E2) on 
ERα-positive cells caused a significant shift in p33(ING1) 
localization from the cytoplasm to the nucleus while it did 
not have an effect on the ERα negative cells (Table 2).
In order to analyze the changes in the subcellular 
localization of p33(ING1b) in the breast carcinoma cell 
lines under the effect of 17β-estradiol (E2) by using 
another method, we also performed immunoblotting 
analysis using nuclear and cytoplasmic cell extracts 
after E2 induction by the conditions described before 
in both MDA-MB-231 and MDA-66 cell lines. We 
found that 17β-estradiol (E2) induction caused increase 
in p33(ING1b) expression in nuclear lysate as well as 
a decrease in cytoplasmic lysate in an ERα-positive 
cell line, MDA-66. However, it did not significantly 
affect p33(ING1b) expression in both compartments 
of an ERα-negative cell line, MDA-MB-231 (Figure 
3A). 17β-Estradiol (E2) enhanced the expression of 
p33(ING1b) in the nuclear compartment 1.76-fold and 
decreased the expression of p33(ING1b) 20-fold in the 
cytoplasmic compartment (Figure 3B).
To evaluate the co-localization of both ERα and 
p33(ING1b) in the nucleus, immunofluorescence staining 
was carried out in MDA-66 cells under the effect of 
17β-estradiol (E2). The number of ERα-positive cells 
MDA - 66  
MDA - MB -231  
Control  (+) E2   
Control  (+) E2  
(A)  
(B)  
Figure 2. p33(ING1b) expression with 17β-estradiol induction. (A) Nuclear staining of p33(ING1b) in ERα-positive MDA-66 cells. 
(B) Cytoplasmic staining of p33(ING1b) in ERα-negative MDA-MB-231 cells. (Experiments were carried out in triplicate. All figures 
have 40× magnification).
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with p33(ING1b) in the nucleus and/or cytoplasm was 
analyzed (Figure 4A). After 17β-estradiol (E2) induction 
in the MDA-66 cell line, the number of cells with nuclear 
p33(ING1b) increased 10-fold, while the number of cells 
with cytoplasmic p33(ING1b) did not change significantly 
(Figure 4B).
Table 2. Subcellular localization of p33(ING1b) expression with stable expression of ERα in MDA-MB-231 cells 
in ligand-dependent or nondependent manner.
ERα (–) cell ERα (+) cell
MDA-MB-231 MDA-66
E2* (+) E2 (–) E2* (+) E2 (–)
p33(ING1b) positive (%)
Cytoplasmic 24 ± 2 31 ± 4 10 ± 2 62 ± 7
Cyto./nuc. 71 ± 4 62 ± 3 61 ± 4 30 ± 4
Nuclear 5 ± 3 5 ± 2 29 ± 3 2 ± 1
p33(ING1b) negative (%) 0 2 ± 2 0 6 ± 2
* 10 nM 17β-estradiol induction for 3 h in sf-DMEM medium
Figure 3. (A) Expression of p33(ING1b) in nuclear and cytoplasmic compartments of cells in both ERα-positive and ERα-
negative cell lines, MDA-MB-231 and MDA-66, respectively. (B) Density analysis of p33(ING1b) bands normalized with 
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Figure 4. Co-localization of ERα and p33(ING1b) expression in MDA-66 cells. (A) Representative pictures for ERα and p33(ING1b) 
expression (upper line: arrows indicate the cells with both ERα and p33(ING1b) expression in nucleus; lower line: arrows indicate the 
cell with nuclear ERα and cytoplasmic p33(ING1b) expression). (B) Fold change in the number of cells with nuclear ERα having nuclear 
and/or cytoplasmic p33(ING1b) under the effect of 17β-estrodiol (E2) induction of MDA-66 cells.
ERα P33(ING1b) merge 
× 40 × 40 × 40 
× 40 × 40 × 40 
(A)
(B)
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4. Discussion
Although ING1 has initially been identified as a tumor 
suppressor gene, mutations in ING1 appear to be extremely 
rare in breast carcinomas, ovarian carcinomas, colorectal 
carcinomas, squamous cell carcinoma of different origins, 
and melanoma (Garkavtsev et al., 1996; Nouman et al., 
2003b). Recently, the loss of nuclear ING expression has 
been described in several human cancers, suggesting that 
it may have a role in abrogation of ING function during 
carcinogenesis (Zhang et al., 2008; Nouman et al., 2002a, 
2002b; Zhu et al., 2013). Nouman et al. showed that 
nuclear expression of p33(ING1b) was downregulated in 
invasive carcinoma of the breast and this alteration was 
significantly associated with more poorly differentiated 
tumors (Nouman et al., 2003a). They also reported a 
similar positive correlation between p33(ING1b) nuclear 
expression and ERα expression similar to what we have 
seen in the present study. This correlation is consistent with 
a function for nuclear ING proteins in directing towards a 
particular cellular fate under the effect of ERα signaling 
through interactions with functional proteins, such as 
HATs and HDACs. p33(ING1b) was shown to interact 
directly with the activation function 2 (AF2) domain of 
ERα and to modulate the transcriptional activity of an 
ERα-responsive reporter construct in a dose-dependent 
manner (Toyama et al., 2003). This also indicates a role 
of nuclear p33(ING1b) in estrogen-responsive signaling 
in mammalian cells. Interestingly, ectopic expression 
of p33(ING1b) protein in cancer cells has a function 
in DNA repair under DNA damage inducing stress in a 
p53-dependent or independent manner as in fibroblasts 
(Mobley and Brueggemeier, 2004; Kuo et al., 2007). It 
has also been shown that DNA damage is also induced 
by estrogen and/or estrogen metabolites with an ER-
dependent manner in breast carcinoma cell lines (Mobley 
and Brueggemeier, 2004; Bianco et al., 2016). Detoxifying 
enzyme activity markedly decreases with treatment with 
17β-estradiol (E2) in MCF-7 cells (ER-positive), leading to 
increased susceptibility of cells to oxidative DNA damage. 
However, E2 has no effect on detoxifying enzyme activity 
in MDA-MB-231 (ER negative) cells (Iso et al., 2006). With 
regard to the established interval for E2 concentration in 
these reports, it is possible to conclude that E2 might cause 
DNA damage inducing stress in ERα-positive MDA-66 
isogenic clone, but not in ERα negative MDA-MB-231; 
then p33(ING1b) goes to the nucleus for its function in 
repair.
 In the present study, we established a correlation 
between ERα expression and the nuclear localization of 
p33(ING1b) in a variety of breast cancers samples. We also 
clearly showed that nuclear localization of p33(ING1b) 
is regulated by 17β-estradiol (E2) in ERα-positive breast 
carcinoma cells. The mechanism demonstrated in the 
present study regarding the p33(INGb) protein shift 
from cytoplasm to nucleus in ERα-positive tumors in 
a hormone-mediated manner could help us to develop 
novel strategies for the diagnosis and treatment of invasive 
breast carcinomas. 
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